Visceral Fat Range for Females: What Is Healthy?

Visceral fat range for females is an important health marker, yet it is widely misunderstood. Unlike subcutaneous fat beneath the skin, visceral fat sits deep within the abdominal cavity, surrounding vital organs, and is closely linked to cardiometabolic risk. Women face particular challenges because hormonal changes across the lifespan, especially around the menopause, can shift fat distribution towards the abdomen. This article explains what a healthy visceral fat range looks like for women, how it is measured, why it changes with age, and what health risks are associated with elevated levels, along with practical guidance on when to seek clinical advice.

What is a healthy visceral fat range for women?

A waist circumference below 80 cm indicates lower risk in women, while consumer scale scores of 1 to 12 are described as healthy, though these are proprietary and not clinically validated. A GP should assess the full picture.

Consumer body composition scales often display a visceral fat score, and many manufacturers (including Tanita and Omron) use a scale on which scores of 1 to 12 are described as within the healthy range, while scores of 13 and above indicate elevated visceral fat. These numerical bands are proprietary to each manufacturer, are not standardised across devices, and are not validated clinical cut-offs. They should not be used in isolation to make health decisions, and any concern should be discussed with a GP who can assess the full clinical picture.

Visceral fat is the metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines. Unlike subcutaneous fat, which sits just beneath the skin, visceral fat is more closely linked to cardiometabolic risk. Women naturally carry a higher proportion of subcutaneous fat than men, but this protective pattern can shift significantly with age and hormonal change.

Waist circumference remains one of the most practical clinical indicators of visceral fat burden. NHS guidance suggests that a waist measurement above 80 cm (approximately 31.5 inches) in women indicates increased health risk, and above 88 cm (approximately 34.6 inches) indicates substantially increased risk. Some international guidance, including from the World Health Organization and the International Diabetes Federation, recommends lower waist thresholds for women of South Asian, Chinese, Japanese and South and Central American descent, reflecting differences in body fat distribution at equivalent body mass index values; however, the exact figures vary between sources and your GP can advise on which thresholds apply to you.

If you are concerned about your visceral fat level, speaking with your GP is the most appropriate first step. They can assess your measurements in the context of your overall health, family history and any existing conditions, and refer you for further investigation if needed.

How is visceral fat measured and what do the numbers mean?

Waist circumference and waist-to-hip ratio are the most practical clinical measures; a waist-to-hip ratio above 0.85 in women signals increased cardiometabolic risk. Consumer BIA scores are estimates and not clinically validated.

Visceral fat is most accurately measured using imaging techniques such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning, which can directly quantify the volume of fat surrounding the abdominal organs. However, these methods are not routinely used in clinical practice for this purpose alone, as they are costly and, in the case of CT, involve radiation exposure.

In everyday clinical and community settings, waist circumference and waist-to-hip ratio are the most widely used proxy measures. Waist-to-hip ratio is calculated by dividing the waist measurement by the hip measurement; a ratio above 0.85 in women is associated with increased cardiometabolic risk according to World Health Organization guidance. Waist-to-height ratio, where a value of 0.5 or above signals increased risk, is also gaining recognition as a simple and inclusive screening tool and is referenced in current NICE guidance on obesity identification.

Consumer bioelectrical impedance analysis (BIA) devices, including smart scales and handheld monitors, provide a visceral fat score or rating based on electrical resistance through body tissues. These scores are estimates rather than direct measurements and can be affected by hydration status, recent exercise and the time of day. Many manufacturers use a scale of 1 to 59, with scores up to 12 described as healthy, 13 to 17 as high and 18 or above as very high, but these thresholds are proprietary, vary between brands and are not clinically validated. They should not be used as a substitute for clinical assessment.

For clinical decision-making, NICE recommends waist circumference as a practical and cost-effective tool. If your GP suspects significant central adiposity, they may arrange blood tests to assess associated metabolic risk factors, including HbA1c or fasting glucose and a lipid profile, as well as a measurement of blood pressure.

Why do women tend to store more visceral fat after the menopause?

Declining oestrogen during the menopause shifts fat storage from the hips and thighs to the abdomen, increasing visceral fat even without weight gain. Poor sleep and reduced activity during this period can compound the effect.

Women tend to accumulate more visceral fat after the menopause primarily because declining oestrogen levels alter the way the body distributes and stores fat, shifting the pattern from the hips and thighs towards the abdomen. This hormonal change is one of the most well-documented drivers of central adiposity in women and helps explain why cardiometabolic risk rises notably in the postmenopausal years.

Oestrogen plays an active role in regulating fat cell function, insulin sensitivity and the activity of enzymes involved in fat storage and breakdown. When oestrogen levels fall during and after the menopause, adipose tissue in the abdominal region becomes more metabolically active in accumulating fat. Changes in cortisol sensitivity and growth hormone secretion during this life stage are also thought to contribute to visceral fat deposition. The result is that even women who maintain a stable overall body weight may notice an increase in waist circumference during this period.

Sleep disruption, which is common during the perimenopause and menopause, can compound this effect. Poor sleep is independently associated with elevated cortisol, increased appetite and preferential storage of fat in the visceral compartment. Reduced physical activity, which may accompany menopausal symptoms such as joint discomfort or fatigue, can also contribute.

Hormone replacement therapy (HRT), sometimes referred to in the literature as menopausal hormone therapy, has been shown in some studies to attenuate the shift towards central fat distribution, though it is not prescribed solely for this purpose and its use must be assessed individually in line with NICE guideline NG23 on menopause. Women who are concerned about changes in body composition around the menopause should discuss their options with their GP or a menopause specialist, who can consider the full clinical picture.

What health risks are linked to high visceral fat in women?

High visceral fat in women significantly raises the risk of type 2 diabetes, cardiovascular disease, MASLD and certain cancers. It drives insulin resistance, dyslipidaemia and chronic inflammation, which together constitute metabolic syndrome.

High visceral fat in women is associated with significantly increased risk of type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease) and certain cancers, including endometrial cancer and postmenopausal breast cancer. These risks arise because visceral fat is not metabolically inert: it releases free fatty acids, inflammatory cytokines and hormones directly into the portal circulation, which supplies the liver and influences systemic metabolism.^[7]

Elevated visceral fat is strongly linked to insulin resistance, a state in which cells respond less effectively to insulin, leading to raised blood glucose and, over time, type 2 diabetes. It is also associated with dyslipidaemia (raised triglycerides and reduced HDL cholesterol), hypertension and low-grade chronic inflammation, all of which contribute to atherosclerosis and cardiovascular risk.^[7][9] Women who carry excess visceral fat may therefore face a cluster of risk factors sometimes described as metabolic syndrome.

The risks are not confined to older women. Conditions such as polycystic ovary syndrome (PCOS), which affects women of reproductive age, are associated with insulin resistance and a tendency towards central fat accumulation, even in women with a body mass index within the normal range, as noted in NICE clinical knowledge summaries on PCOS.^[11][14] This underlines why waist circumference and visceral fat assessment can provide clinically meaningful information beyond BMI alone.

If you have a waist circumference above the thresholds recommended by NHS guidance, or if a body composition assessment suggests elevated visceral fat, it is worth discussing this with your GP. They can arrange appropriate blood tests and advise on lifestyle modifications, including dietary changes and increased physical activity, which are the most evidence-based approaches to reducing visceral fat.^[5] Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be explored alongside lifestyle measures.

Frequently Asked Questions